GlassScriptPhysician profile
Angelo C Arcilla
NPI 1821093394
$18,375.96
in general payments reported to CMS, 2019-2025
47 companies · $1,369 in 2025
The $1,369 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,443 · 2020: $2,092 · 2021: $3,160 · 2022: $3,439 · 2023: $3,575 · 2024: $2,299 · 2025: $1,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,242.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $3,092.06 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $2,130.50 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,902.60 | 2019-2025 | Farxiga, Breztri, Lokelma |
| Novo Nordisk INC | $1,769.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,743.72 | 2019-2025 | Jardiance, Ofev, Jascayd |
| Abbvie INC. | $1,151.68 | 2019-2024 | Linzess, Creon |
| Bayer Healthcare Pharmaceuticals INC. | $790.91 | 2021-2024 | |
| Amgen INC. | $657.56 | 2019-2025 | Repatha, Evenity, Prolia |
| Merck Sharp & Dohme LLC | $594.48 | 2019-2025 | Belsomra, Verquvo, Januvia |
| Lilly USA, LLC | $573.68 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $407.19 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $347.37 | 2019-2025 | Xifaxan |
| Exact Sciences Corporation | $309.87 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $282.49 | 2019-2022 | |
| Astellas Pharma US INC | $222.87 | 2020-2025 | Myrbetriq, Veozah |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angelo Arcilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.